Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations.

CONCLUSIONS: Findings from "omics" trials should be used to learn more about biologic targeted drugs, and to select more specific drugs matching patient's distinctive molecular profile. Specific markers of inflammation such as percentage of eosinophils are important in determining sensitivity/resistance to corticosteroids. Specific gene variations (Single nucleotide polymorphisms: SNPs) may influence drug sensitivity or resistance. Clinicians working in a real-world need to have a suitable interpretation of molecular results together with a treatment guidance and recommendations. Far more translational research is required before new results from omics techniques can be applied in personalized medicine in real-world settings. PMID: 29852859 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29852859?dopt=Abstract

Source: Current Medicinal Chemistry - May 31, 2018 Category: Chemistry Authors: Russo P, Lococco F, Kisialiou A, Prinzi G, Lamonaca P, Cardaci V, Fini M Tags: Curr Med Chem Source Type: research